IN VITRO AND IN VIVO EFFICACY OF TRASTUZUMAB DERUXTECAN (T-DXD) IN EPITHELIAL OVARIAN CANCER WITH HER2/NEU OVEREXPRESSION

被引：0

作者：

Mutlu, Levent ^{[1
]}

Manavella, Diego ^{[1
]}

Bellone, Stefania ^{[1
]}

Santin, Alessandro ^{[1
]}

机构：

[1] Yale Univ, Obstet Gynecol & Reprod Sci, New Haven, CT USA

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2022年 / 32卷

关键词：

D O I：

10.1136/ijgc-2022-igcs.106

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EP015/#546

引用

页码：A54 / A54

页数：1

共 50 条

[41] Trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing salivary duct carcinoma: Subgroup analysis of two phase 1 studies.
Bando, Hideaki
Kinoshita, Ichiro
Modi, Shanu
Tsurutani, Junji
Bang, Yung-Jue
Iwata, Hiroji
Sato, Yuta
Nakatani, Shunsuke
Lee, Caleb C.
Sugihara, Masahiro
Okuda, Yasuyuki
Takahashi, Shunji
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[42] A PHASE 1/2 STUDY OF SBT6050 COMBINED WITH TRASTUZUMAB DERUXTECAN (T-DXD) OR TRASTUZUMAB AND TUCATINIB WITH OR WITHOUT CAPECITABINE IN PATIENTS WITH HER2-EXPRESSING OR HER2-AMPLIFIED CANCERS
Klempner, Samuel
Strickler, John
Gourley, Lindsey
Jacquemont, Celine
Bhatia, Vinona
Hunder, Naomi
Odegard, Valerie
Piha-Paul, Sarina
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A426 - A426
[43] Trastuzumab deruxtecan (T-DXd) in patients with HER2+metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.
Jerusalem, Guy Heinrich Maria
Park, Yeon Hee
Yamashita, Toshinari
Hurvitz, Sara A.
Modi, Shanu
Andre, Fabrice
Krop, Ian E.
Gonzalez, Xavier
Hall, Peter S.
You, Benoit
Saura, Cristina
Kim, Sung-Bae
Osborne, Cynthia R. C.
Sagara, Yasuaki
Tokunaga, Eriko
Liu, Yali
Cathcart, Jillian
Lee, Caleb C.
Perrin, Christophe
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[44] Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer
Wolff, Antonio C.
Mcshane, Lisa M.
Allison, Kimberly H.
NEW ENGLAND JOURNAL OF MEDICINE, 2025, 392 (08) : 829 - 831
[45] Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice
Okamoto, Hiromi
Oitate, Masataka
Hagihara, Katsunobu
Shiozawa, Hideyuki
Furuta, Yoshitake
Ogitani, Yusuke
Kuga, Hiroshi
XENOBIOTICA, 2020, 50 (10) : 1242 - 1250
[46] Valemetostat and trastuzumab deruxtecan (T-DXd) in previously treated advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric cancer or gastro-esophageal junction (GEJ) adenocarcinoma.
Shitara, Kohei
Enzinger, Peter C.
Mohapatra, Avani
Janjigian, Yelena Y.
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS508 - TPS508
[47] Exposure-response (ER) analyses of efficacy and safety of trastuzumab deruxtecan (T-DXd) to inform dosing recommendation in HER2-mutant non-small cell lung cancer (NSCLC)
Khatri, Amit
Polhamus, Daniel
Cobbina, Enoch
Garcia, Ramon
Yoder, Todd
Abutarif, Malaz
Garimella, Tushar
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[48] HER2/neu oncoprotein overexpression in epithelial ovarian cancer: Evaluation of its prevalence and prognostic significance - Clinical study
Verri, E
Guglielmini, P
Puntoni, M
Perdelli, L
Papadia, A
Lorenzi, P
Rubagotti, A
Ragni, N
Boccardo, F
ONCOLOGY, 2005, 68 (2-3) : 154 - 161
[49] EVALUATION OF HER2/neu EXPRESSION IN OVARIAN EPITHELIAL TUMOURS
Arya, P. R.
Varghese, Sheela
Sankar, S.
JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS, 2018, 7 (15): : 1883 - 1887
[50] DESTINY-PanTumor02 study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Exploratory biomarker analyses of HER2 expression and gene amplification in tissue and plasma
Makker, V.
Lee, J-Y.
Oh, D-Y.
Oaknin, A.
Puvvada, S. D.
Cecchi, F.
Mcewen, R.
Michelini, F.
Meric-Bernstam, F.
ANNALS OF ONCOLOGY, 2023, 34 : S239 - S240

← 1 2 3 4 5 →